

Hsu AP, Korzeniowska A, Aguilar CC, Gu J, Karlins E, Oler AJ, Chen G, Reynoso GV, Davis J, Chaput A, Peng T, Sun L, Lack JB, Bays DJ, Stewart ER, Waldman SE, Powell DA, Donovan FM, Desai JV, Pouladi N, Long Priel DA, Yamanaka D, Rosenzweig SD, Niemela JE, Stoddard J, Freeman AF, Zerbe CS, Kuhns DB, Lussier YA, Olivier KN, Boucher RC, Hickman HD, Frelinger J, Fierer J, **Shubitz LF**, Leto TL, Thompson GR 3rd, Galgiani JN, Lionakis MS, Holland SM. Immunogenetics associated with severe coccidioidomycosis. *JCI Insight*. 2022 Nov 22;7(22). doi: 10.1172/jci.insight.159491. PubMed PMID: 36166305; PubMed Central PMCID: PMC9746810.

Shubitz LF, Powell DA, Dial SM, Butkiewicz CD, Trinh HT, Hsu AP, Buntzman A, Frelinger JA, Galgiani JN. Reactivation of Coccidioidomycosis in a Mouse Model of Asymptomatic Controlled Disease. *J Fungi (Basel)*. 2022 Sep 21;8(10). doi: 10.3390/jof8100991. PubMed PMID: 36294555; PubMed Central PMCID: PMC9605249.

Kirkland TN, Stevens DA, Hung CY, Beyhan S, Taylor JW, **Shubitz LF**, Duttke SH, Heidari A, Johnson RH, Deresinski SC, Lauer A, Fierer J. *Coccidioides* Species: A Review of Basic Research: 2022. *J Fungi (Basel)*. 2022 Aug 16;8(8). doi: 10.3390/jof8080859. Review. PubMed PMID: 36012847; PubMed Central PMCID: PMC9409882.

Galgiani JN, **Shubitz LF**, Orbach MJ, Mandel MA, Powell DA, Klein BS, Robb EJ, Ohkura M, Seka DJ, Tomasiak TM, Monath TP. Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of *Coccidioides Posadasii* as a Viable Candidate for Human Trials. *J Fungi (Basel)*. 2022 Aug 10;8(8). doi: 10.3390/jof8080838. Review. PubMed PMID: 36012826; PubMed Central PMCID: PMC9410110.

O'Shaughnessy E, Yasinskaya Y, Dixon C, Higgins K, Moore J, Reynolds K, Ampel NM, Angulo D, Blair JE, Catanzaro A, Galgiani JN, Garvey E, Johnson R, Larwood DJ, Lewis G, Purdie R, Rex JH, **Shubitz LF**, Stevens DA, Page SJ, Shukla SJ, Farley JJ, Nambiar S. FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. *Clin Infect Dis*. 2022 Jun 10;74(11):2061-2066. doi: 10.1093/cid/ciab904. PubMed PMID: 34651656.

Mandel MA, Beyhan S, Voorhies M, **Shubitz LF**, Galgiani JN, Orbach MJ, Sil A. The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen *Coccidioides posadasii*. *PLoS Pathog*. 2022 Apr;18(4):e1009832. doi: 10.1371/journal.ppat.1009832. eCollection 2022 Apr. PubMed PMID: 35385558; PubMed Central PMCID: PMC9015156.

Powell DA, Hsu AP, **Shubitz LF**, Butkiewicz CD, Moale H, Trinh HT, Doetschman T, Georgieva TG, Reinartz DM, Wilson JE, Orbach MJ, Holland SM, Galgiani JN, Frelinger JA. Mouse Model of a Human STAT4 Point Mutation That Predisposes to Disseminated Coccidiomycosis. *Immunohorizons*. 2022 Feb 11;6(2):130-143. doi: 10.4049/immunohorizons.2200007. PubMed PMID: 35149520; PubMed Central PMCID: PMC9235507.

Powell DA, **Shubitz LF**, Butkiewicz CD, Trinh HT, Donovan FM, Frelinger JA, Galgiani JN. TNF α Blockade Inhibits Both Initial and Continued Control of Pulmonary *Coccidioides*. Front Cell Infect Microbiol. 2021;11:796114. doi: 10.3389/fcimb.2021.796114. eCollection 2021. PubMed PMID: 35174101; PubMed Central PMCID: PMC8841766.

Powell DA, Hsu AP, Butkiewicz CD, Trinh HT, Frelinger JA, Holland SM, Galgiani JN, **Shubitz LF**. Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis. Front Cell Infect Microbiol. 2021;11:790488. doi: 10.3389/fcimb.2021.790488. eCollection 2021. PubMed PMID: 35071044; PubMed Central PMCID: PMC8777018.

Butkiewicz CD, **Shubitz LF**, Nix DE. A preliminary study of the plasma concentrations of orally administered fluconazole in alpacas (*Vicugna pacos*). J Vet Pharmacol Ther. 2022 Jan;45(1):99-106. doi: 10.1111/jvp.12994. Epub 2021 Jun 24. PubMed PMID: 34165194.

Shubitz LF, Robb EJ, Powell DA, Bowen RA, Bosco-Lauth A, Hartwig A, Porter SM, Trinh H, Moale H, Bielefeldt-Ohmann H, Hoskinson J, Orbach MJ, Frelinger JA, Galgiani JN. Δ cps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine. 2021 Nov 16;39(47):6894-6901. doi: 10.1016/j.vaccine.2021.10.029. Epub 2021 Oct 23. PubMed PMID: 34696935; PubMed Central PMCID: PMC9186468.

Butkiewicz CD, Alcott CJ, Renschler J, Wheat LJ, **Shubitz LF**. The utility of *Coccidioides* antigen and antibody detection in cerebrospinal fluid in the diagnosis of canine central nervous system coccidioidomycosis. Am J Vet Res. 2021 Nov 12;83(1):59-63. doi: 10.2460/ajvr.21.08.0121. PubMed PMID: 34773701.

Shubitz LF, Schlacks S, Vishkautsan P, Butkiewicz CD, Worthing KA. Posaconazole treatment of refractory coccidioidomycosis in dogs. J Vet Intern Med. 2021 Nov;35(6):2772-2777. doi: 10.1111/jvim.16282. Epub 2021 Oct 18. PubMed PMID: 34658074; PubMed Central PMCID: PMC8692207.

Shubitz LF, Powell DA, Butkiewicz CD, Lewis ML, Trinh HT, Frelinger JA, Orbach MJ, Galgiani JN. A Chronic Murine Disease Model of Coccidioidomycosis Using *Coccidioides posadasii*, Strain 1038. J Infect Dis. 2021 Jan 4;223(1):166-173. doi: 10.1093/infdis/jiaa419. PubMed PMID: 32658292; PubMed Central PMCID: PMC7781464.

Izquierdo A, Jaffey JA, Szabo S, Struthers J, Okwumabua O, Hostnik ET, Ohkura M, Trinh H, **Shubitz LF**, Orbach MJ, White ME. *Coccidioides posadasii* in a Dog With Cervical Dissemination Complicated by Esophageal Fistula. Front Vet Sci. 2020;7:285. doi: 10.3389/fvets.2020.00285. eCollection 2020. PubMed PMID: 32509812; PubMed Central PMCID: PMC7248623.

Schlacks S, Vishkautsan P, Butkiewicz C, **Shubitz L**. Evaluation of a commercially available, point-of-care *Coccidioides* antibody lateral flow assay to aid in rapid diagnosis of coccidioidomycosis in dogs. Med Mycol. 2020 Apr 1;58(3):328-332. doi: 10.1093/mmy/myz067. PubMed PMID: 31212311.

Arbona N, Butkiewicz CD, Keyes M, **Shubitz LF**. Clinical features of cats diagnosed with coccidioidomycosis in Arizona, 2004-2018. *J Feline Med Surg*. 2020 Feb;22(2):129-137. doi: 10.1177/1098612X19829910. Epub 2019 Feb 20. PubMed PMID: 30784342.

Donovan FM, **Shubitz L**, Powell D, Orbach M, Frelinger J, Galgiani JN. Early Events in Coccidioidomycosis. *Clin Microbiol Rev*. 2019 Dec 18;33(1). doi: 10.1128/CMR.00112-19. Print 2019 Dec 18. Review. PubMed PMID: 31619396; PubMed Central PMCID: PMC6927309.

Butkiewicz CD, **Shubitz LF**. Coccidioidomycosis in alpacas in the southwestern United States. *Transbound Emerg Dis*. 2019 Mar;66(2):807-812. doi: 10.1111/tbed.13088. Epub 2018 Dec 14. PubMed PMID: 30506909.

Davidson AP, **Shubitz LF**, Alcott CJ, Sykes JE. Selected Clinical Features of Coccidioidomycosis in Dogs. *Med Mycol*. 2019 Feb 1;57(Supplement_1):S67-S75. doi: 10.1093/mmy/myy113. Review. PubMed PMID: 30690600.

Shubitz LF, Powell DA, Trinh HT, Lewis ML, Orbach MJ, Frelinger JA, Galgiani JN. Viable spores of *Coccidioides posadasii* Δ cps1 are required for vaccination and provide long lasting immunity. *Vaccine*. 2018 May 31;36(23):3375-3380. doi: 10.1016/j.vaccine.2018.04.026. Epub 2018 Apr 30. PubMed PMID: 29724507; PubMed Central PMCID: PMC6139032.

Wiederhold NP, **Shubitz LF**, Najvar LK, Jaramillo R, Olivo M, Catano G, Trinh HT, Yates CM, Schotzinger RJ, Garvey EP, Patterson TF. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by *Coccidioides posadasii* and *Coccidioides immitis*. *Antimicrob Agents Chemother*. 2018 Apr;62(4). doi: 10.1128/AAC.02258-17. Print 2018 Apr. PubMed PMID: 29437615; PubMed Central PMCID: PMC5913997.

Shubitz LF, Roy ME, Trinh HT, Hoekstra WJ, Schotzinger RJ, Garvey EP. Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs. *Antimicrob Agents Chemother*. 2017 May;61(5). doi: 10.1128/AAC.00111-17. Print 2017 May. PubMed PMID: 28289027; PubMed Central PMCID: PMC5404554.